התחייבויות לטווח ארוך של החברה: Dr. Reddy's Laboratories Limited (RDY)

Dr. Reddy's Laboratories is ramping up R&D and biosimilars, expanding its presence in emerging markets. Assessing the company's current level of long-term debt on GURU.Markets, we find that the indicator remains around 0.13. This occurs against a backdrop of severe pricing pressure in the generics sector. Meanwhile, the holding's plants maintain high capacity utilization, undergoing scheduled workshop modernization according to GMP standards.

Investors must identify the fundamental factors of an asset's financial stability. This metric aggregates all credit obligations with a maturity of over one year, measuring the total volume of borrowed capital. By analyzing the trajectory of the company's long-term debt, one can assess the debt service risk amid changing interest rates. For Dr. Reddy's Laboratories (RDY), these funds are critical for financing R&D centers and retaining high-paid chemists in Western branches.